Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ
Pierre Fabre Laboratories introduced global dermo-cosmetics brands Avène, Klorane and René Furterer to the US market in the 1990's. With an ever-growing desire for French dermo-cosmetics, the US dermo-cosmetics business has become a top priority. Building upon their success in oncology and dermatology in Europe and Asia, the company has recently expanded its medical care investments in the US through the creation of a dedicated pharmaceutics unit, Pierre Fabre Pharmaceuticals (PFP). This subsidiary is focused on continuing to deliver breakthrough therapies in rare diseases and oncology to American patient populations with high unmet needs and limited treatment options.
Eric Ducournau, CEO of Pierre Fabre Laboratories states, "we have declared the United States a priority geography for the company. The US is not only the biggest market in the world for pharmaceuticals and cosmetics alike, but also the most disruptive market for therapeutic innovation. For 15 years, we have built strategic partnerships with highly innovative US biotechnology companies in the fields of oncology, rare diseases, and medical dermatology. We have also multiplied by 10 times the turnover of our blockbuster brand Eau Thermale Avène since 2010, and its potential remains huge given the growing appetite of American consumers for cosmetics designed and tested with the same rigor as for medicines. We are now determined to walk the next step forward and the opening of our new office in Secaucus with plans to expand in the rare diseases and oncology business is a testimony to this dedication."
Secaucus, NJ offers a strategic location with excellent transportation links to New York City and the broader tri-state area. Designed to represent the company's core values, the office showcases its deep respect for the environment, a commitment to sustainable innovation and allows for hands on learning through an onsite space that offers an immersive skin and hair care experience. This thoughtfully curated environment is engineered to spark creativity and foster teamwork across all departments.
"This new office is more than just a space, it's a hub for collaboration, innovation, and showcases the team's hard work and dedication. It embodies the Group's commitment to pushing boundaries across both business units in derm-cosmetics and pharmaceutics, while providing New Ways to Care for all" said Lisa Morris, President and CEO of Pierre Fabre USA.
"Today's office opening demonstrates the steadfast commitment of Pierre Fabre Laboratories to building a powerful presence for medical innovation and patient impact in the US," said Adriana Herrera, CEO of PFP. "Leveraging our strength as a humanitarian foundation owned company, PFP has been focused over the past 18-months on building the US Medical Care operations and to bring on board an experienced, agile and purpose driven US team focused on creating long-term value and hope for patients, by delivering innovative therapies to people living with cancer who are in urgent need of effective, life-extending treatment options."
With this new footprint in the US, Pierre Fabre Laboratories is positioning itself for even greater impact with American patients and healthcare professionals in dermo-cosmetics and pharmaceuticals. For the company, this is only the beginning.
For more information, visit pierre-fabre.com, pierrefabrepharmaceuticals.com or follow @aveneusa on Instagram
Note: High-resolution images, interviews, and product samples are available upon request.
ABOUT PIERRE FABRE LABORATORIES Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow, and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care, and family health care.
In 2024, Pierre Fabre Laboratories posted 3.1 billion euros in revenues, 70% of which came from international sales in 120 countries. Based in southwest France since its creation and manufacturing nearly 90% of its products in France, Pierre Fabre Laboratories employs 10,200 people worldwide. Its R&D budget amounted to 220 million euros in 2024, of which 60% is allocated to targeted therapies in oncology and 35% to skin health and care solutions.
Pierre Fabre Laboratories' majority shareholder (86%) is an eponymous humanitarian Foundation. Employees constitute the company's other shareholders. This capital structure guarantees the company's independence, long-term vision, and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world.
Pierre Fabre Laboratories' CSR policy has been assessed by AFNOR Certification and has been awarded the "Exemplary" level of its CSR label (ISO 26 000 standard for sustainable development).
For more information, visit www.pierre-fabre.com
Media Contact:Elena Suarez-PeñaElena.suarez@pierre-fabre.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pierre-fabre-laboratories-begins-next-chapter-in-secaucus-nj-302485335.html
SOURCE Avène USA
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
4 hours ago
- Los Angeles Times
Trump tax law could cause Medicare cuts if Congress doesn't act, CBO says
WASHINGTON — The federal budget deficits caused by President Trump's tax and spending law could trigger automatic cuts to Medicare if Congress does not act, the nonpartisan Congressional Budget Office reported Friday. The CBO estimates that Medicare, the federal health insurance program for Americans over age 65, could potentially see as much as $491 billion in cuts from 2027 to 2034 if Congress does not act to mitigate a 2010 law that forces across-the-board cuts to many federal programs once legislation increases the federal deficit. The latest report from CBO showed how Trump's signature tax and spending law could put new pressure on federal programs that are bedrocks of the American social safety net. Trump and Republicans pledged not to cut Medicare as part of the legislation, but the estimated $3.4 trillion that the law adds to the federal deficit over the next decade means that many Medicare programs could see cuts. In the past, Congress has always acted to mitigate cuts to Medicare and other programs, but it would take some bipartisan cooperation to do so. Democrats, who requested the analysis from CBO, jumped on the potential cuts. 'Republicans knew their tax breaks for billionaires would force over half a trillion dollars in Medicare cuts — and they did it anyway,' Rep. Brendan Boyle of Pennsylvania, the top Democrat on the House Budget Committee, said in a statement. 'American families simply cannot afford Donald Trump's attacks on Medicare, Medicaid and Obamacare.' Hospitals in rural parts of the country are already grappling with cuts to Medicaid, which is available to people with low incomes, and cuts to Medicare could exacerbate their shortfalls. As Republicans muscled the bill through Congress and are now selling it to voters back home, they have been critical of how the CBO has analyzed the bill. They have also argued that the tax cuts will spur economic growth and pointed to $50 billion in funding for rural hospitals that was included in the package. Groves writes for the Associated Press.
Business Insider
4 hours ago
- Business Insider
CNFinance announce ADS ratio change
CNFinance (CNF) announced that it plans to change the ratio of its American depositary shares to its Class A ordinary shares, par value $0.0001 per share, from the current ratio of one ADS to 20 Class A ordinary shares to a new ratio of one one ADS to 200 Class A ordinary shares. For the company's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS split. A post-effective amendment to the ADS Registration Statement on Form F-6 will be filed with the SEC to reflect the change in the ADS Ratio. The company anticipates that the change in the ADS Ratio will be effective on or about September 5, subject to the effectiveness of the post-effective amendment to the ADS registration statement on Form F-6 on or before that date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
5 hours ago
- Business Insider
Foresight Autonomous plans to conduct 1-for-7 reverse stock split
Foresight Autonomous (FRSX) announced that it plans to conduct a reverse share split of the company's outstanding ordinary shares, no par value per share, at a ratio of 1-for-7 which is expected to be implemented at market open on the Tel-Aviv Stock Exchange on August 24, and on the Nasdaq Capital Market on August 25. There will be no change to the existing ratio of the number of ordinary shares represented by the company's American Depositary Shares. However, as a result of the reverse share split, the ADS price is expected to increase proportionally, although the company can give no assurance that the ADS price after the reverse share split will be equal to or greater than the ADS price on a proportionate basis. The company believes that the reverse share split will help the company to maintain compliance with Nasdaq listing requirements. However, the company can give no assurance that this goal will be achieved. As of the effective date for the reverse share split, the company's ADSs will continue to be traded on the Nasdaq under the symbol 'FRSX' with a new CUSIP Number. Elevate Your Investing Strategy:
